Sign Up Today and Learn More About 4D Molecular Therapeutics Stock
Invest in or calculate the value of your shares in 4D Molecular Therapeutics or other pre-IPO companies through EquityZen's platform.
4D Molecular Therapeutics Stock
4D Molecular Therapeutics’ mission is to design and develop transformative gene therapy products using our proprietary.
About 4D Molecular Therapeutics Stock
Founded
2013
Headquarters
Emeryville, CA, US
Total Funding
10.0M
Industries
Science and Engineering, Health Care, Biotechnology
4D Molecular Therapeutics, we are unlocking the full potential of the gene therapy field. Our customized AAV vectors can deliver genes to any cell in the body to eradicate disease.
4D Molecular Therapeutics Press Mentions
Stay in the know about the latest news on 4D Molecular Therapeutics
Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
Endpoints News • May 01, 2018
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy ...
Business Wire (press release) • Apr 30, 2018
4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for ...
Business Wire (press release) • Sep 19, 2017
4D Molecular Therapeutics Management
Leadership team at 4D Molecular Therapeutics
Co-Founder
David Schaffer
COO
Anthony Davies
Join now and verify your accreditation status to gain access to:
- 4D Molecular Therapeutics Current Valuation
- 4D Molecular Therapeutics Stock Price
- 4D Molecular Therapeutics Management
- Available deals in 4D Molecular Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- 4D Molecular Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- 4D Molecular Therapeutics Revenue and Financials
- 4D Molecular Therapeutics Highlights
- 4D Molecular Therapeutics Business Model
- 4D Molecular Therapeutics Risk Factors
- 4D Molecular Therapeutics Research Report from SACRA Research
Trading 4D Molecular Therapeutics Stock
How to invest in 4D Molecular Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like 4D Molecular Therapeutics through EquityZen funds. These investments are made available by existing 4D Molecular Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell 4D Molecular Therapeutics stock?
Shareholders can sell their 4D Molecular Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."